Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Top Cited Papers
- 1 January 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 9 (1) , 64-71
- https://doi.org/10.1038/nrc2545
Abstract
Viruses have been engineered for cancer therapy in a variety of ways. Approaches include non-replicating gene therapy vectors, cancer vaccines and oncolytic viruses, but the clinical efficacy of these approaches has been limited by multiple factors. However, a new therapeutic class of oncolytic poxviruses has recently been developed that combines targeted and armed approaches for treating cancer. Initial preclinical and clinical results show that products from this therapeutic class can systemically target cancers in a highly selective and potent fashion using a multi-pronged mechanism of action.Keywords
This publication has 132 references indexed in Scilit:
- Chemical control of protein stability and function in living miceNature Medicine, 2008
- Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase geneCancer Gene Therapy, 2007
- Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunizationJournal of General Virology, 2007
- The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaProceedings of the National Academy of Sciences, 2006
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsProceedings of the National Academy of Sciences, 2006
- Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-βBlood, 2006
- Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell FunctionJournal of Virology, 2006
- The Hallmarks of CancerCell, 2000
- Structure of vaccinia virus late promotersJournal of Molecular Biology, 1989